SmithKline Beecham
Executive Summary
Four compounds entering "advanced" clinicals are the anti- virals famciclovir/penciclovir for genital herpes and herpes zoster infection in immune-compromised patients; ropinirole for Parkinson's disease; topotecan as a treatment for solid tumors; and SK&F 105657 for benign prostatic hypertrophy, company notes in its recently-released annual report for 1991. SB says these are the "leading candidates" among 10 or more new products it "is committed to filing in our major markets over the next five years".